Vimian Group Ab · OMXSTO:VIMIAN
Vimian Group Ab — Q3 2026 Earnings Presentation
16 slides from Vimian Group Ab's earnings presentation, October 2026
Slide 1: Q3 presentation
Improving animal health through science and technology for better lives Q3 presentation October 2026
Slide 2: Q3 Highlights
Q3 Highlights Continued strong performance / Strong revenue and earnings growth / Continued double-digit organic growth / Improved cash flow from operations / Acquisition of Norfolk Medical Products – enters soft tissue surgery
Slide 3: Strong momentum in the third quarter
Strong momentum in the third quarter Revenue and Adj. EBITA x% Adj EBITA margin x% Organic growth (%) Q3 development / Net revenue +15% 130 121.6 / 15% revenue growth to EUR 120.3m 116.0 120.3 120 109.0 29.2 29.7 29.2 110 107.5 30 104.3 104.3 100 25.4 25.5 26.1 / 11% organic growth with positive 28.
Slide 4: Specialty Pharma
Specialty Pharma Underlying momentum remains strong +7% Organic revenue growth / 7 per cent organic growth with double-digit growth in the therapeutic areas Allergy, +12% Dermatology and Specialty Pharmaceuticals Adj. EBITA growth / Launched next version of allergy test platform PAX / YoY profitabil
Slide 5: MedTech
MedTech +15% Organic revenue Continued double-digit growth growth / 15 per cent organic growth with double-digit growth in both dental and orthopedics +20% Adj. EBITA growth / Educated 1,300 veterinarians in the quarter to unlock market growth / Margin uplift driven by strong growth and improved gro
Slide 6: Veterinary Services
Veterinary Services Momentum remains +10% Organic revenue growth / 10 per cent organic growth and 12,400 member clinics by the end of Q3 / Officially entered the new markets Portugal and Japan +28% Adj. EBITA growth / Margin improvement included positive effects in the quarter from mix and partner a
Slide 7: Diagnostics
Diagnostics Focus on companion animal +13% Organic revenue growth / 13 per cent organic growth driven by extraction and PCR sales in livestock / Margin improvement driven by revenue growth, partly offset by investments to +111% Adj. EBITA growth diversify into companion animal Revenue and Adj. EBITA
Slide 8: M&A developments
M&A developments / Five acquisitions year to date Acquisition Segment Closing Revenues I-Vet Diagnostics March 2026 EUR 5.6m Favna Vet Services March 2026 EUR 4.3m VetSave Vet Services May 2026 EUR 1.7m Verona Pet Diagnostics July 2026 EUR 0.4m Norfolk MedTech November 2026 USD 6.9m Page 9
Slide 9: Acquiring leading niche provider within soft tissue surgery
Acquiring leading niche provider within soft tissue surgery / Norfolk Medical Products* in US – a specialist provider of implantable solutions for long-term or chronic interventions, including vascular access ports and products for urinary, pulmonary and fluid-management procedures / Adding annual r
Slide 10: Creating a sustainable leader in animal health
Creating a sustainable leader in animal health Sustainability strategy Animals People Planet We improve animal health We create a great place to work in We minimize our environmental through innovation, education, an engaging and inclusive footprint by reducing emissions. and responsible treatments.
Slide 11: Third Quarter Financials
2 Third Quarter Financials Page 12
Slide 12: Q3 Income Statement
EURm Q3 2026 July – Sept Q3 2025 July – Sept Q3 Income Statement Net revenue 120.3 104.3 / Operating profit (EBIT) grew 17% to EUR 20.5m Adjusted EBITA 29.2 25.5 / Items affecting comparability of EUR -2.1m (-1.7) Adjusted EBITA margin (%) 24.3% 24.5% / Net financial items of EUR -6.9m (-4.1) Items
Slide 13: Q3 Cash Flow
EURm Q3 2026 July – Sept Q3 2025 July – Sept Q3 Cash Flow EBIT 20.5 17.5 / NWC EUR 116.4m at 25 per cent of revenue per end of Cash flow from operating activities September 22.2 13.7 before change in NWC • Compared to end of June 2026, net working capital increased by EUR 2.3m Change in NWC 0.3 - 2.
Slide 14: Net Debt and Leverage
Leverage Net Debt (EUR m) Net Debt and Leverage 280 274 / Net debt per 30 September 2026 EUR 262.4m 261 258 262 260 254 245 / Cash and cash equivalents EUR 55.6m 240 222 220 212 / Net Debt / LTM Proforma Adjusted EBITDA 2.0x 200 180 160 140 120 2.0x 2.1x 2.1x 2.0x 2.1x 2.1x 2.0x 100 1.8x 80 60 40 20
Slide 15: Concluding remarks
Concluding remarks / Continued strong performance / Five acquisitions closed year-to-date / Clear progress across strategic initiatives / Well-positioned to continue delivering sustainable, volume-led growth combined with value-creative M&A / Strategy deep-dive on Capital Markets Day 24 November Pag
Slide 16: Slide 16